Cancer Biology · global
Same DNA Damage, Different Paths for Tumors: Genetic Background Rewrites Cancer Evolution
Researchers repeatedly induced liver tumors in mice with four different genetic backgrounds and found that inherited genetic differences influence which driver mutations cancer cells select, whether they duplicate their entire genome, and which early cell populations survive.
Cancer is not determined solely by mutations acquired over time. A mouse study published in *Nature* shows that even when sex, living environment, and carcinogen exposure are the same, an individual’s inherited genetic background may still push tumors onto different evolutionary paths. The findings provide direct experimental evidence for why similar DNA damage does not necessarily lead to the same cancer risk.
The research team administered the same dose of diethylnitrosamine (DEN) to male mice from four genetically distinct inbred strains. This chemical causes DNA damage and induces tumors in the liver. The researchers analyzed 581 tumors using histopathology, whole-genome sequencing, and transcriptome sequencing to compare how tumors formed and differentiated after controlling for external conditions.
Tumors from all four genetic backgrounds largely converged on the same endpoint: 95% carried potential driver mutations that activate the MAPK signaling pathway, including mutations in Braf, Hras, Egfr, or Kras. However, the preferred genes and specific amino acid changes differed among strains. In other words, although carcinogenic pressure pushed cells toward similar biological pathways, the cellular environment created by the inherited genome altered which mutation offered the greatest growth advantage.
Differences also emerged in the threshold for tumor formation. In C3H mice, which were the most susceptible to liver tumors, tumors typically contained only one identifiable driver event; tumors in the other strains often required at least two. C3H tumors also retained more early subclones, indicating that multiple cell lineages could continue to coexist, whereas the more resistant strains underwent stronger lineage elimination. Based on this, the researchers speculated that certain genetic backgrounds may allow cells to begin expanding after fewer key changes.
Inherited differences also affected genome stability. The strains showed different patterns in mutation burden, whole-genome duplication, and chromosomal abnormalities. In CAROLI mice, a substantial proportion of tumors exhibited whole-genome duplication that may have occurred early. These results indicate that genetic background influences not only susceptibility to tumor development but also repair, selection, and clonal competition after DNA damage.
However, this was an experiment involving liver tumors induced by a specific chemical carcinogen in male mice. It cannot be used to directly infer that differences in human ancestry would produce the same results, nor is it sufficient to immediately change individual screening or treatment approaches. Its greater significance is that it demonstrates that genetic differences of modest magnitude can indeed reshape cancer evolution. Further validation in human tumors and additional cancer types will be needed to determine whether this information can be used for more refined risk assessment, prevention, and treatment selection.